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Abstract 
Background: Tramadol is a drug used to control severe pain. Various 
side effects of this drug have been reported, one of the most important 
is seizures. The exact cause of tramadol-induced seizures is not known. 
The aim of this study was to investigate the effect of tramadol addiction 
on convulsion and related factors in 2018. 
Methods: This cross-sectional study was performed on 216 patients 
with convulsion referred to Imam Hossain hospital of Shahroud in 
2018. After reviewing and stabilizing vital signs, a questionnaire 
containing demographic information, medical history, medication use 
(especially tramadol), and drugs was completed by patients. The 
association between recurrent convulsion and predictors were assessed 
using multivariable logistic regression. Data were analyzed and 
compared using SPSS statistical software, version 16 and related 
statistical tests. The significant level was set at 0.05. 
Results: In this study from 216 participants, 154 (71.3%) of them were 
male and the rest were female. The mean age of the all patients was 
44.8±18.2 years (17-72 years) that was no significant difference 
between the two groups. Recurrent convulsion was significantly 
associated with history of opium use (Pvalue<0.032) and tramadol 
using (Pvalue<0.001) and there was no significant relationship with 
other variables. Tramadol using cans double your chances of having a 
recurrent convulsion [OR=2(95% CI: 1.752–2.689)]. 
Conclusions: The results of this study showed that taking tramadol in 
opium users can increase the incidence of recurrent convulsion, but 
more research is needed to fully confirm this. 
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Introduction 
Tramadol is a painkiller with morphine-like properties and 
is used to control moderate to severe pain. It is used to treat 
relatively severe acute and chronic pain, can be used at 
different ages and in both sexes, and due to its pleasant 
properties, most of the required dose is used.1,2 It has also been 
used as a viable alternative to drugs.3 It is based on the 
replication of the molecular structure of narcissus, which is one 
of the alkaloids of opium. It is a central painkiller but is not 
chemically similar to opium compounds.4 The mechanism of 
action is not fully understood, but it is likely to bind to opioid 
receptors and inhibit the reuptake of norepinephrine and 
serotonin reuptake.4-5 The antidepressant effect of tramadol is 
one-tenth of that of morphine. Oral absorption of the drug is 
rapid and almost complete, but its bioavailability is 75%. It is 
mainly excreted by the liver and excreted by the kidneys (30% 
unchanged and 60% as metabolites).6-8 The drug is available in 
various forms of tablets, capsules, drops, suppositories, and 
injections, but its oral form is more commonly used in humans. 
Severe pain in orthopedic, gynecological, burns, and chronic 
and incurable diseases, including cancers, is a good platform 
for the use of this drug and is added to its daily use.9-10 Due to 
the lack of serious control over the use of this drug on the one 
hand and its pleasant, sedative, and accessible properties, it has 
been significantly abused by patients, especially addicts, and 
due to its uncontrolled use, the side effects of the drug it is 
noticeable.11-12 The side effects of the drug are many and 
varied, with a long list, including general fatigue and weakness, 
dilation of blood vessels, anxiety, dizziness, balance disorders, 
nervous conditions, sleep disorders, abdominal pain, anorexia, 
increased bowel or constipation, skin rash, visual disturbances, 
frequent urination and seizures are the most important. These 
are the drugs,12-14 but the most important is drug dependence 
(methadone addiction) and seizures. The severity of seizures in 
tramadol users is not exactly known, but various studies have 
reported between 3 and 10% in different places and in different 
communities.15 The most common type of seizure seen in 
professional tramadol users is the generalized type and it’s 
tonic-colonic, which is sometimes very long and dangerous and 
will cause irreversible side effects.10 Tramadol-induced 
seizures are usually generalized and tonic-colonic, with the 
whole body contracting, cyanosis, biting the tongue, mydriasis, 
tachycardia, high blood pressure, and then jumping in different 
parts of the body.10-12 The whole convulsion lasts one minute 
and then the post-ictal phase begins.13 Because the use of this 
drug is very common, especially as an addictive substance in 
the community and especially among young people, and due to 
the lack of accurate statistics on the incidence of seizures and 
other important and dangerous side effects of the drug in 
tramadol users, the aim of this study was to investigate the 
effect of tramadol addiction on convulsion and related factors 
in patients referred to Imam Hossain hospital in Shahroud in 2018. 
Materials and Methods  
This cross-sectional study was performed on all patients 
with the first seizure who referred to Imam Hossain hospital in 
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Shahroud between January and December 2018, who were 
satisfied with participating in the above plan. 
In this study, eligible patients were selected by simple 
census method to complete the sample size, based on having or 
not having a history of tramadol using, they were divided into 
exposed and unexposed groups and compared in the study. The 
exposed group included those who already using or had a 
history of tramadol using. Tramadol use or positive history of 
tramadol use means that patient had used one or two tablets or 
ampoules of tramadol continuously and at least daily for the 
past six months, and this use had continued until for at least 
two weeks before the start of the study. The unexposed group 
was included people without using tramadol in the past six 
months. Then patients in both groups were asked about clinical 
and demographic information including age, sex, convulsion 
times, duration of convulsion, history of specific and long-term 
drug use, alcohol, and opium use, history of the underlying 
disease, and educational level and were recorded in a special 
sheet. Then the patients were monitored for one month and all 
those who suffered from recurrent seizures during this period. 
The relationship between recurrent convulsion and history of 
using tramadol and all other predictors including Moore’s 
factors were assessed using a multivariable regression model. 
Descriptive statistics including mean and standard 
deviation, as well as relative frequency were used to describe 
the data. To examine the relationships and comparisons 
between the two groups, was used the chi-square test and 
multivariate logistic regression were used to evaluate the odds 
of each of the variables. All analyzes were performed using 
SPSS software version 16 and the significant level was set at 
0.05. Sample size using Epi info 7.2 at a significant level of 5% 
and a power of 80%, equal to 108 people in each group and a 
total of 216 people. 
This study has an ethics code number 
(IR.SHMU.REC.1397.166) from the research deputy of 
Shahroud university of medical sciences. The essential 
information and the objectives of the study were explained to 
the patients, and written consent was obtained for participation 
in the plan. 
Results 
In this study from 216 participants (those who have 
seizures for the first time), 154 (71.3%) of them were male and 
the rest were female. The mean age of all patients was 
44.8±18.2 years (17-72 years) that was no significant 
difference between the two groups. The mean BMI of all 
patients was 24.1±3.5 kg/m2 that there was no significant 
difference between the two groups. Also in the tramadol group 
the average time for using tramadol was 14.15±8.28 months 
and the average dosage tramadol used was 37.25±29.75 
mg/day. The demographic, clinical, and laboratory data of the 
two groups are listed in table 1.  
In this study, independent variables related to convulsion 
were investigated in multivariate regression model. As shown 
in table 2, recurrent convulsion as a dichotomous response 
variable was significantly associated with a history of opium 
use (Pvalue<0.032) and tramadol use (Pvalue<0.001) and there 
was no significant relationship with other variables. The results 
of this study also showed that using tramadol can double the 
chances of convulsion [OR=2(95% CI: 1.752–2.689)]. The 
results of the multivariate logistic regression model are 
presented in table 2. 
Table 1. The demographic, clinical and lab information of patients with convulsion in beginning of study 
Demographic & clinical information 
Tramadol used group 
Mean±SD/Number (%) 
No tramadol used group 
Mean±SD/Number (%) 
Total 
Mean±SD/Number (%) 
Pvalue 
Age (year) 46.3±20.9 42.9±17.3 44.8±18.2 0.088 
Age category 
 < 20 years 
 20- 40 years 
 40-60 years 
 > 60 years 
 
14(12.9) 
22(20.4) 
47(43.5) 
25(23.2) 
 
12(11.0) 
25(23.2) 
46(42.6) 
25(23.2) 
 
26(12.0) 
47(21.7) 
93(43.1) 
50(23.2) 
 
 
0.095 
Sex 
 Male 
 Female 
 
74(68.5) 
34(31.5) 
 
80(74.1) 
28(25.9) 
 
154(71.3) 
62(28.7) 
 
0.059 
BMI (kg/m2) 24.3±3.5 23.9±3.4 24.1±3.5 0.213 
History of sedative use 
 Positive 
 Negative 
 
38(35.2) 
70(64.8) 
 
35(32.4) 
73(67.6) 
 
73(33.8) 
143(66.2) 
 
0.109 
History of opium use 
 Positive 
 Negative 
 
21(19.4) 
87(80.6) 
 
18(16.7) 
90(85.3) 
 
39(18.1) 
177(81.9) 
 
0.081 
History of alcohol use 
 Positive 
 Negative 
 
11(10.2) 
97(89.8) 
 
12(11.1) 
96(88.9) 
 
23(10.6) 
193(89.4) 
 
0.141 
BS (mg/dl)  85.1±18.5 92.8±16.7 88.6±17.3 0.095 
Calcium serum (mg/dl) 9.1±1.7 8.8±2.1 8.9±1.9 0.103 
BUN (mg/dl) 67.4±25.6 65.9±26.4 66.3±25.9 0. 091 
Hemoglobin (g/dl) 12.7±1.9 13.1±2.1 12.9±1.9 0.184 
EKG 
 Normal 
 Abnormal 
 
94(87.1) 
14(12.9) 
 
97(89.8) 
11(10.2) 
 
191(88.4) 
25(11.6) 
 
0.092 
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Table 2. Relationship between independent variables with recurrent convulsion in multivariate logistic regression model 
Independent variables Odds ratio 95% Confidence Pvalue 
Age category (year)     
 <20 
 20 to 40 
 40 to 60 
 >60 
 
1.000 
1.016 
1.077 
1.161 
0.085-1.142 
0.088-1.238 
0.091-1.351 
0.093 
0.075 
0.053 
Sex     
 Female 
 Male 
 
1.000 
1.125 
0.815-1.213 0.069 
Body mass index (kg/m2)     
 18-25 
 <18 
 >25 
 
1.000 
1.323 
0.881 
0.996-1.385 
0.612-1.105 
0.059 
0.085 
History of sedative use     
 Negative 
 Positive 
 
1.000 
1.151 
0.871-1.323 0.103 
History of opium use       
 Negative 
 Positive 
 
1.000 
1.496 
1.109-1.842 0.032 
History of alcohol use     
 Negative 
 Positive 
 
1.000 
1.179 
0.891-1.367 0.096 
BS(mg/dl)      
 >70 
 <70 
 
1.000 
1.289 
1.016-1.363 0.071 
Calcium serum (mg/dl)      
 >8.5 
 <8.5 
 
1.000 
1.228 
0.968-1.382 0.079 
BUN (mg/dl)      
 <40 
 >40 
 
1.000 
1.028 
0.857-1.282 0.079 
Hemoglobin (g/dl)      
 <11 
 >11 
 
1.000 
1.147 
0.869-1.377 0.101 
EKG     
 Normal 
 Abnormal 
 
1.000 
1.081 
0.855-1.218 0.088 
Tramadol using     
 Negative 
 Positive 
 
1.000 
2.089 
1.752-2.689 0.001 
 
Discussion 
The results of this study showed that taking tramadol could 
significantly increase the chances of recurrent convulsion 
(OR=2). It has also been shown that a history of opium use can 
significantly increase the chances of recurrent convulsion. This 
finding is fully consistent with the results of Rehni, Sansone, 
and Talaie and is largely consistent with the findings of Afshari 
and Katz.16-20 
Complications of medications, especially tramadol, are one 
of the major problems for all people in Iran and other 
developing countries. Identifying the cause and amount of 
consumption is very important and vital and is the key to 
treating this problem. Due to the variety of causes, it is 
important to know the dangerous side effects of controlling the 
disease.21-22 
Tramadol is one of the most widely used addictive drugs in 
developing countries and one of the most important etiological 
factors of drug abuse in Iran, especially among young people.23 
In the present study, it was found that in patients with 
seizures, addiction to sedatives with 33.8% and then opium 
addiction with 18.1%, the use of these drugs was much higher 
in patients of tramadol group. This is somewhat different from 
the results of Thundiyil study, which found that opium and 
alcohol use were the most common in patients with 
convulsion.24 The reason for this difference may be related to 
the choice of study groups, sample size, geographical area, 
social and cultural status and time of patients' visit to medical 
centers, but by studying other researchers such as Moreno-Izco 
and Jovanović-Cupić is quite compatible.25-26 
The results of this study also showed that a history of 
opium significant, which may be due to inexperience and 
excessive tramadol use by adolescents. Although these findings 
are different from studies conducted in European countries, 
they are in good agreement with studies conducted in 
developing countries.29-30 
Because taking tramadol can play a role in many problems, 
especially seizures, and this disorder is the cause of a chronic 
and debilitating disease, we expect to see a reduction in these 
problems with timely control.31 Therefore, information about 
the incidence of tramadol-induced seizures, sources and 
methods of occurrence and exacerbation of risk factors for 
tramadol-induced complications,32 control and management of 
drug use among patients and especially young people are 
important and due to the abundance and availability Tramadol, 
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more extensive studies and the use of stronger and more 
consistent rules to control the use of this drug, especially in 
Iran, can be considered.33-34 
The results of this study showed that taking tramadol can 
increase the incidence of recurrent convulsion and this increase 
will increase more in opium users. But more research is needed 
to fully confirm this. Therefore, all patients with convulsion, 
especially recurrent convulsion, and young people should be 
screened for tramadol using and, if identified, monitored as 
soon as possible. 
One of the limitations of the present study is the type of 
study (cross-sectional) which can limit the possibility of 
examining all the factors affecting the occurrence of seizures in 
tramadol consumers and also the patients' self-expression for 
taking tramadol. 
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